Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ABVX
ABIVAX S.A.
NASDAQ
$113.35
▼ DOWN 0.83% (-0.95)

KEY STATISTICS

Market Cap$8.32 B
52w High$148.83
52w Low$69.81
Dividend Yield—
Frequency—
P/E-59.41
Volume926.19K
Shares Out.73.43M

COMPANY

LEADERSHIP

Marc de Garidel
CHIEF EXECUTIVE
Marc de Garidel

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 20, 2023
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
80

PRICE TARGET

Target High$180.00
Target Low$90.00
Target Median$158.00
Target Consensus$152.71

UPCOMING EARNINGS

DateSep 21, 2026
DayMonday
Rev. Est.$778.45K
SEP
21
MON

PRICE

$113.35 ▼ DOWN 0.83% (−$0.95)
$112$113$114$1159:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM113.35

About Abivax S.A.

https://www.abivax.com ↗

ABIVAX develops and optimizes drugs for inflammatory, infectious, and cancer diseases, with lead candidates in various clinical trial phases targeting conditions like ulcerative colitis, COVID-19, HIV, cancer, and viral infections.

INDUSTRY

Biotechnology

A PRODUCT ABIVAX S.A. IS KNOWN FOR

Obefazimod
Obefazimod

Obefazimod, an oral, once-daily drug in late-stage development for ulcerative colitis and Crohn's disease, is Abivax's lead asset with a novel mechanism that boosts miR-124 to regulate inflammation.

COMPETITORS

COMPETITOR
ABBV COMPARE
JNJ COMPARE
LLY COMPARE
PFE COMPARE
TEVA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
73
LISTED HERE
17
RANKED BY POSITION SIZE
IBB
0.53% · 483.8K
SCHF
0.03% · 169.7K
GVIP
1.98% · 99.6K
SPDW
0.02% · 61.1K
ATFV
1.49% · 57.7K
VXUS
0.00% · 28.3K
ONEQ
0.02% · 14.7K
AADR
2.74% · 9.4K
MEDI
1.86% · 7.1K
GURU
1.19% · 6.6K
IBBQ
0.42% · 3.6K
WELL.L
2.38% · 3.2K
APIE
0.03% · 2.6K
BIB
0.23% · 2.1K
PINK
0.01% · 220
ESIM
0.13% · 182
TNXT
0.05% · 80

INSTITUTIONAL OWNERSHIP

SHARES OWNED
47.40%
HOLDERS
378
TOP 12 OF 378 · RANKED BY POSITION SIZE
Tcg Crossover Management, LLC
7.1M sh · $959.03M
Ubs Group AG
4.5M sh · $506.35M
Darwin Global Management, Ltd.
3.6M sh · $348.22M
Morgan Stanley
3.2M sh · $425.06M
Point72 Asset Management, L.P.
2.9M sh · $248.36M
Helikon Investments Ltd
2.8M sh · $371.41M
Vestal Point Capital, LP
2.3M sh · $313.09M
Cormorant Asset Management, LP
1.9M sh · $165.56M
Adar1 Capital Management, LLC
1.8M sh · $240.49M
Paradigm Biocapital Advisors LP
1.6M sh · $132.8M
Caligan Partners LP
1.6M sh · $207.61M
Citadel Advisors LLC
1.4M sh · $191.67M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 3
MARKET OUTPERFORM 2
OUTPERFORM 1
NEUTRAL 1
11 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Truist Securities BUY Citizens MARKET OUTPERFORM Jefferies BUY Leerink Partners OUTPERFORM BTIG BUY Wedbush NEUTRAL Morgan Stanley OVERWEIGHT

SECTORS PEERS

PEERPRICE
JAZZ$244.54COMPARE
HALO$105.35COMPARE
MDGL$533.76COMPARE
CORT$113.88COMPARE
AXSM$199.02COMPARE
CYTK$72.09COMPARE
RYTM$107.17COMPARE